LGM
VRDN icon

Logos Global Management’s Viridian Therapeutics VRDN Stock Holding History

Logos Global Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-700,000
Closed -$12.3M – 74
2024
Q1 		$12.3M Buy
700,000
+100,000
+17% +$1.94M 0.99% 30
2023
Q4 		$13.1M Sell
600,000
-450,000
-43% -$7.1M 1.22% 22
2023
Q3 		$16.1M Sell
1,050,000
-75,000
-7% -$1.43M 2.15% 16
2023
Q2 		$26.8M Buy
1,125,000
+175,000
+18% +$4.49M 3.64% 10
2023
Q1 		$24.2M Sell
950,000
-50,000
-5% -$1.6M 3.46% 11
2022
Q4 		$29.2M Hold
1,000,000
– – 3.42% 10
2022
Q3 		$20.5M Buy
+1,000,000
New +$18M 2.52% 16
2021
Q4 		– Sell
-1,500,000
Closed -$24.7M – 79
2021
Q3 		$24.7M Buy
+1,500,000
New +$22M 1.78% 19
2021
Q2 		– Sell
-550,000
Closed -$9.19M – 66
2021
Q1 		$9.19M Hold
550,000
– – 0.9% 24
2020
Q4 		$9.05M Buy
+550,000
New +$8.29M 0.78% 28

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Logos Global Management's VRDN Position: Q2 2024 in Review

Logos Global Management sold out of Viridian Therapeutics (VRDN) in Q2 2024, closing a stake of 700,000 shares — an estimated $12.3M sold.

Logos Global Management first reported a position in VRDN in Q4 2020 and held it in 10 quarters. The position peaked at $29.2M in Q4 2022. 138 funds tracked by Wall St. Rank hold VRDN as of Q2 2024.

  • Logos Global Management reported no remaining Viridian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Logos Global Management sold 700,000 Viridian Therapeutics shares in Q2 2024, an estimated $12.3M.
  • Logos Global Management first reported a position in Viridian Therapeutics in Q4 2020 and held it in 10 quarters.
  • Logos Global Management's Viridian Therapeutics position peaked at $29.2M in Q4 2022.
  • 138 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2024.

Based on Logos Global Management's 13F filing for Q2 2024, filed 14 Aug 2024.